Cost-Effectiveness of the Aerobika® Oscillating Positive Expiratory Pressure Device in the Management of Chronic Obstructive Pulmonary Disease Exacerbations in Canada
Background. The Aerobika® oscillating positive expiratory pressure (OPEP) device is a hand-held, drug-free medical device that has been shown to improve lung function and improve health-related quality of life in patients with chronic obstructive pulmonary disease (COPD). We estimated the cost-effec...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2019-01-01
|
| Series: | Canadian Respiratory Journal |
| Online Access: | http://dx.doi.org/10.1155/2019/9176504 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849308183003136000 |
|---|---|
| author | Nguyen Xuan Thanh Philip Jacobs Jason Suggett Andrew McIvor Alan Kaplan |
| author_facet | Nguyen Xuan Thanh Philip Jacobs Jason Suggett Andrew McIvor Alan Kaplan |
| author_sort | Nguyen Xuan Thanh |
| collection | DOAJ |
| description | Background. The Aerobika® oscillating positive expiratory pressure (OPEP) device is a hand-held, drug-free medical device that has been shown to improve lung function and improve health-related quality of life in patients with chronic obstructive pulmonary disease (COPD). We estimated the cost-effectiveness of this device among postexacerbation COPD patients in the Canadian healthcare system. Methods. We performed a cost-utility analysis using a Markov model to compare both costs and outcome of patients with COPD who had recently experienced an exacerbation between 2 treatment arms: patients who used the Aerobika® device and patients who did not use the Aerobika® device. This cost-utility analysis included costs based on the Alberta healthcare system perspective as these represent Canadian experience. A one-year horizon with 12 monthly cycles was used. Results. For a patient after 1 year, the use of the Aerobika® device would save $694 in healthcare costs and produce 0.04 more in quality-adjusted life years (QALYs) in comparison with no positive expiratory pressure (PEP)/OPEP therapy. In other words, the economic outcome of the device was dominant (i.e., more effective and less costly). The probability for this device to be the dominant strategy was 72%. With a willingness to pay (WTP) threshold of $50,000 per QALY gained, the probability for the Aerobika® device to be cost-effective was 77%. Conclusions. Given one of the major treatment goals in the GOLD guidelines is to minimize the negative impact of exacerbations and prevent re-exacerbations, the Aerobika® OPEP device should be viewed as a potential component of a treatment strategy to improve symptom control and reduce the risk of re-exacerbations in patients with COPD. |
| format | Article |
| id | doaj-art-0eeb1f3cf0624e618b2e374cb1ecfe3f |
| institution | Kabale University |
| issn | 1198-2241 1916-7245 |
| language | English |
| publishDate | 2019-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Canadian Respiratory Journal |
| spelling | doaj-art-0eeb1f3cf0624e618b2e374cb1ecfe3f2025-08-20T03:54:32ZengWileyCanadian Respiratory Journal1198-22411916-72452019-01-01201910.1155/2019/91765049176504Cost-Effectiveness of the Aerobika® Oscillating Positive Expiratory Pressure Device in the Management of Chronic Obstructive Pulmonary Disease Exacerbations in CanadaNguyen Xuan Thanh0Philip Jacobs1Jason Suggett2Andrew McIvor3Alan Kaplan4Institute of Health Economics, 1200 10405 Jasper Avenue, Alberta, CanadaDepartment of Medicine, University of Alberta, Edmonton, Alberta, CanadaTrudell Medical International, London, Ontario, CanadaMcMaster University, Hamilton, Ontario, CanadaDepartment of Family and Community Medicine, University of Toronto, Toronto, Ontario, CanadaBackground. The Aerobika® oscillating positive expiratory pressure (OPEP) device is a hand-held, drug-free medical device that has been shown to improve lung function and improve health-related quality of life in patients with chronic obstructive pulmonary disease (COPD). We estimated the cost-effectiveness of this device among postexacerbation COPD patients in the Canadian healthcare system. Methods. We performed a cost-utility analysis using a Markov model to compare both costs and outcome of patients with COPD who had recently experienced an exacerbation between 2 treatment arms: patients who used the Aerobika® device and patients who did not use the Aerobika® device. This cost-utility analysis included costs based on the Alberta healthcare system perspective as these represent Canadian experience. A one-year horizon with 12 monthly cycles was used. Results. For a patient after 1 year, the use of the Aerobika® device would save $694 in healthcare costs and produce 0.04 more in quality-adjusted life years (QALYs) in comparison with no positive expiratory pressure (PEP)/OPEP therapy. In other words, the economic outcome of the device was dominant (i.e., more effective and less costly). The probability for this device to be the dominant strategy was 72%. With a willingness to pay (WTP) threshold of $50,000 per QALY gained, the probability for the Aerobika® device to be cost-effective was 77%. Conclusions. Given one of the major treatment goals in the GOLD guidelines is to minimize the negative impact of exacerbations and prevent re-exacerbations, the Aerobika® OPEP device should be viewed as a potential component of a treatment strategy to improve symptom control and reduce the risk of re-exacerbations in patients with COPD.http://dx.doi.org/10.1155/2019/9176504 |
| spellingShingle | Nguyen Xuan Thanh Philip Jacobs Jason Suggett Andrew McIvor Alan Kaplan Cost-Effectiveness of the Aerobika® Oscillating Positive Expiratory Pressure Device in the Management of Chronic Obstructive Pulmonary Disease Exacerbations in Canada Canadian Respiratory Journal |
| title | Cost-Effectiveness of the Aerobika® Oscillating Positive Expiratory Pressure Device in the Management of Chronic Obstructive Pulmonary Disease Exacerbations in Canada |
| title_full | Cost-Effectiveness of the Aerobika® Oscillating Positive Expiratory Pressure Device in the Management of Chronic Obstructive Pulmonary Disease Exacerbations in Canada |
| title_fullStr | Cost-Effectiveness of the Aerobika® Oscillating Positive Expiratory Pressure Device in the Management of Chronic Obstructive Pulmonary Disease Exacerbations in Canada |
| title_full_unstemmed | Cost-Effectiveness of the Aerobika® Oscillating Positive Expiratory Pressure Device in the Management of Chronic Obstructive Pulmonary Disease Exacerbations in Canada |
| title_short | Cost-Effectiveness of the Aerobika® Oscillating Positive Expiratory Pressure Device in the Management of Chronic Obstructive Pulmonary Disease Exacerbations in Canada |
| title_sort | cost effectiveness of the aerobika r oscillating positive expiratory pressure device in the management of chronic obstructive pulmonary disease exacerbations in canada |
| url | http://dx.doi.org/10.1155/2019/9176504 |
| work_keys_str_mv | AT nguyenxuanthanh costeffectivenessoftheaerobikaoscillatingpositiveexpiratorypressuredeviceinthemanagementofchronicobstructivepulmonarydiseaseexacerbationsincanada AT philipjacobs costeffectivenessoftheaerobikaoscillatingpositiveexpiratorypressuredeviceinthemanagementofchronicobstructivepulmonarydiseaseexacerbationsincanada AT jasonsuggett costeffectivenessoftheaerobikaoscillatingpositiveexpiratorypressuredeviceinthemanagementofchronicobstructivepulmonarydiseaseexacerbationsincanada AT andrewmcivor costeffectivenessoftheaerobikaoscillatingpositiveexpiratorypressuredeviceinthemanagementofchronicobstructivepulmonarydiseaseexacerbationsincanada AT alankaplan costeffectivenessoftheaerobikaoscillatingpositiveexpiratorypressuredeviceinthemanagementofchronicobstructivepulmonarydiseaseexacerbationsincanada |